Millennium's Velcade injection shows 40% response rate in multiple myeloma patients

By Elaine Rigoli

Tampa, Fla., June 5 - Millennium Pharmaceuticals, Inc. said new clinical data for the treatment of multiple myeloma in newly diagnosed patients showed an overall response rate of 40% as a single agent, including a complete response rate of 10% and a 30% partial response rate.

The phase 2 prospective, single-arm study assessed the safety and efficacy of Velcade in 66 patients with untreated, symptomatic multiple myeloma. Patients received single-agent Velcade 1.3 mg/m2 twice weekly for two weeks every 21 days for eight cycles.

This data provides further rationale for several phase 2 studies of Velcade in combination with other therapies that consistently have shown some of the highest recorded response rates, including complete responses, the company said in a news release.

Millennium is a biopharmaceutical company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.